100487-82-9

Usage

Uses

Used in Pharmaceutical and Chemical Research:
Methyl 2-(4-bromo-2-nitrophenyl)acetate is utilized as a synthetic building block for the creation of a wide array of organic molecules. Its unique structure and reactivity contribute to the development of new compounds with specific therapeutic or chemical properties.
Used in Medicinal Chemistry:
Due to its potential biological activities, Methyl 2-(4-bromo-2-nitrophenyl)acetate is employed in medicinal chemistry for the exploration of its possible applications in drug discovery. Its properties may contribute to the design of new pharmaceutical agents with targeted effects on biological systems.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 2-(4-bromo-2-nitrophenyl)acetate is used as a versatile intermediate for the preparation of complex organic compounds. Its reactivity and functional groups make it suitable for various synthetic pathways, leading to the formation of diverse chemical entities.
Used in Industrial Applications:
Beyond the laboratory, Methyl 2-(4-bromo-2-nitrophenyl)acetate finds use in various industrial applications where its chemical properties are leveraged for specific processes or products. Its solubility in organic solvents and stability make it a candidate for use in formulations and reactions within the industry.

Upstream product

• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 67-56-1 methanol 
• 6127-11-3 (4-bromo-2-nitrophenyl)acetic acid 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 108-59-8 malonic acid dimethyl ester 
• 100487-81-8 2-(4-bromo-2-nitro-phenyl)malonic acid dimethyl ester 

Downstream Products

• 544709-66-2 2-(4-bromo-2-nitro-phenyl)-2-methyl-propionic acid methyl ester 
• 651780-27-7 ethyl 6-bromobenzo[d]isoxazole-3-carboxylate 
• 1202765-53-4 methyl 4-(4-bromo-2-nitrophenyl)tetrahydro-2H-pyran-4-carboxylate 
• 1190866-02-4 6’-bromospiro[cyclohexane-1,3’-indolin]-2’-one 
• 6127-11-3 (4-bromo-2-nitrophenyl)acetic acid 
• 1093631-76-5 methyl {3-nitro-4'-[(phenylmethyl)oxy]-4-biphenylyl}acetate 
• 1202765-70-5 methyl 2-(4-bromo-2-nitrophenyl)acrylate 
• 1190861-39-2 6'-bromospiro[cyclobutane-1,3'-indolin]-2'-one 
• 1093631-49-2 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1H-indazole-3-carboxylic acid 
• 1093631-78-7 1-(1,1-dimethylethyl) 3-methyl 6-(4-hydroxyphenyl)-1H-indazole-1,3-dicarboxylate 
• 1093631-77-6 methyl {3-(acetylamino)-4'-[(phenylmethyl)oxy]-4-biphenylyl}acetate 
• 1259513-65-9 1-(3-methyl-2-phenyl-4-quinolinyl)-6-(4-morpholinyl)-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-pyran] 
• 1202765-56-7 6-bromo-2',3',5',6'-tetrahydrospiro[dihydroindole-3,4'-pyran] 

Relevant academic research and scientific papers

AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF

The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical com

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS

Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

TRIAZOLOPYRAZINE DERIVATIVES

Compounds of the formula (I) in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

Iron(II) bromide-catalyzed intramolecular c-h bond amination [1,2]-shift tandem reactions of aryl azides

Iron(II) bromide catalyzes the transformation of ortho-substituted aryl azides into 2,3-disubstituted indoles through a tandem ethereal C-H bond amination [1,2]-shift reaction. The preference for the 1,2-shift component of the tandem reaction was established to be Me 1 2 Ph.

Indolin-2-one p38α inhibitors I: Design, profiling and crystallographic binding mode

The use of structure-based design and molecular modeling led to the discovery of indolin-2-one derivatives as potent and selective p38α inhibitors. The predicted binding mode was confirmed by X-ray crystallography.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

ALKYNYL ALCOHOLS AS KINASE INHIBITORS

Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

PROTEIN KINASE INHIBITORS

This invention relates to selenophene compounds of formula (I) shown below; each variable in formula (I) is defined in the specification. These compounds can be used to treat cancer.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceu

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.